DAVENPORT & Co LLC Has $90 Million Stock Position in Enovis Corporation $ENOV

DAVENPORT & Co LLC cut its holdings in shares of Enovis Corporation (NYSE:ENOV) by 7.4% in the 2nd quarter, Holdings Channel reports. The firm owned 2,843,135 shares of the company’s stock after selling 228,850 shares during the period. DAVENPORT & Co LLC’s holdings in Enovis were worth $89,999,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in shares of Enovis by 266.7% during the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after acquiring an additional 692 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock valued at $74,000 after purchasing an additional 725 shares in the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Enovis during the 1st quarter valued at approximately $198,000. Finally, McIlrath & Eck LLC increased its position in Enovis by 52.2% during the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock worth $202,000 after purchasing an additional 1,808 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling

In other Enovis news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average cost of $29.71 per share, with a total value of $74,275.00. Following the transaction, the chief financial officer owned 116,729 shares in the company, valued at approximately $3,468,018.59. The trade was a 2.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was acquired at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at $3,182,260.41. This trade represents a 6.71% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 12,157 shares of company stock valued at $374,760 over the last quarter. Insiders own 2.70% of the company’s stock.

Enovis Price Performance

Shares of ENOV opened at $32.02 on Monday. The business has a 50-day moving average of $30.09 and a 200-day moving average of $32.03. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -2.25 and a beta of 1.69. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.83.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $564.50 million during the quarter, compared to the consensus estimate of $555.80 million. During the same quarter in the prior year, the firm posted $0.62 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, equities research analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research reports. Needham & Company LLC decreased their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Canaccord Genuity Group lowered their target price on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 8th. Evercore ISI dropped their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a report on Saturday, September 27th. Finally, UBS Group dropped their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.